From 2003-2007, 12 preclinical drugs were required to yield one marketed drug, but then jumped to 24 from 2005 through 2009, and 30 between from 2007 through 2011.
The company has added to the required payout when necessary to keep the distribution growing for 17 consecutive quarters, and the latest dividend yield puts it just short of 7%.